Resistance of Porphyromonas gingivalis ATCC 33277 to direct killing by antimicrobial peptides is protease independent

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 638-642

  Bachrach, Gilad ^a   Altman, Hamutal ^a   Kolenbrander, Paul E ^b   Chalmers, Natalia I ^b   Gabai Gutner, Michal ^a   Mor, Amram ^c   Friedman, Michael ^d   Steinberg, Doron ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLLEUCYLTRYPTOPHYLLYSYLTHREONYLLEUCYLLEUCYLLYSYLLYSYLVALYLLEUCYLLYSYLALANYLALANYLALANINAMIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; LYSYLARGINYLLEUCYLPHENYLALANYLLYSYLLYSYLLEUCYLLEUCYLPHENYALANYLSERYLLEUCYLARGINYLLYSYLTYROSINAMIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENANTIOMER; ENZYME BINDING; ENZYME DEGRADATION; ESCHERICHIA COLI; HYDROLYSIS; INNATE IMMUNITY; NONHUMAN; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SEQUENCE; ANTIMICROBIAL CATIONIC PEPTIDES; DRUG RESISTANCE, BACTERIAL; HISTATINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE HYDROLASES; PORPHYROMONAS GINGIVALIS;

EID: 38649128484     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01271-07     Document Type: Article

References (45)

1. Altman, H., D. Steinberg, Y. Porat, A. Mor, D. Fridman, M. Friedman, and G. Bachrach. 2006. In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J. Antimicrob. Chemother. 58:198-201.
2. Bals, R., X. Wang, M. Zasloff, and J. M. Wilson. 1998. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA 95:9541-9546.
3. Bowdish, D. M., D. J. Davidson, Y. E. Lau, K. Lee, M. G. Scott, and R. E. Hancock. 2005. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77:451-459.
4. Brissette, C. A., and S. A. Lukehart. 2007. Mechanisms of decreased susceptibility to β-defensins by Treponema denticola. Infect. Immun. 75:2307-2315.
5. Brissette, C. A., and S. A. Lukehart. 2002. Treponema denticola is resistant to human β-defensins. Infect. Immun. 70:3982-3984.
6. Brogden, K. A., J. M. Guthmiller, M. Salzet, and M. Zasloff. 2005. The nervous system and innate immunity: the neuropeptide connection. Nat. Immunol. 6:558-564.
7. Burns, E., G. Bachrach, L. Shapira, and G. Nussbaum. 2006. Cutting Edge: TLR2 is required for the innate response to Porphyromonas gingivalis: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. J. Immunol. 177:8296-8300.
8. Collins, L. V., S. A. Kristian, C. Weidenmaier, M. Faigle, K. P. Van Kessel, J. A. Van Strijp, F. Gotz, B. Neumeister, and A. Peschel. 2002. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186:214-219.
9. Devine, D. A. 2003. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol. Immunol. 40:431-443.
10. Devine, D. A., P. D. Marsh, R. S. Percival, M. Rangarajan, and M. A. Curtis. 1999. Modulation of antibacterial peptide activity by products of Porphyromonas gingivalis and Prevotella spp. Microbiology 145:965-971.
11. Feder, R., A. Dagan, and A. Mor. 2000. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J. Biol. Chem. 275:4230-4238.
12. Fields, G. B., and R. L. Noble. 1990. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35:161-214.
13. Giacometti, A., O. Cirioni, W. Kamysz, G. D'Amato, C. Silvestri, M. S. Del Prete, A. Licci, A. Riva, J. Lukasiak, and G. Scalise. 2005. In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrob. Agents Chemother. 49:1249-1252.
14. Groenink, J., A. L. Ruissen, D. Lowies, W. van 't Hof, E. C. Veerman, and A. V. Nieuw Amerongen. 2003. Degradation of antimicrobial histatin-variant peptides in Staphylococcus aureus and Streptococcus mutans. J. Dent. Res. 82:753-757.
15. Guthmiller, J. M., K. G. Vargas, R. Srikantha, L. L. Schomberg, P. L. Weistroffer, P. B. McCray, Jr., and B. F. Tack. 2001. Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob. Agents Chemother. 45:3216-3219.
16. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
17. Helmerhorst, E. J., I. M. Reijnders, W. van't Hof, I. Simoons-Smit, E. C. Veerman, and A. V. Amerongen. 1999. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemother. 43:702-704.
18. Helmerhorst, E. J., W. van't Hof, P. Breeuwer, E. C. Veerman, T. Abee, R. F. Troxler, A. V. Amerongen, and F. G. Oppenheim. 2001. Characterization of histatin 5 with respect to amphipathicity, hydrophobicity, and effects on cell and mitochondrial membrane integrity excludes a candidacidal mechanism of pore formation. J. Biol. Chem. 276:5643-5649.
19. Helmerhorst, E. J., W. Van't Hof, E. C. Veerman, I. Simoons-Smit, and A. V. Nieuw Amerongen. 1997. Synthetic histatin analogues with broad-spectrum antimicrobial activity. Biochem. J. 326:39-45.
20. Hosokawa, I., Y. Hosokawa, H. Komatsuzawa, R. B. Goncalves, N. Karimbux, M. H. Napimoga, M. Seki, K. Ouhara, M. Sugai, M. A. Taubman, and T. Kawai. 2006. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clin. Exp. Immunol. 146:218-225.
21. Joly, S., C. Maze, P. B. McCray, Jr., and J. M. Guthmiller. 2004. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42:1024-1029.
22. Kolenbrander, P. E., N. S. Jakubovics, N. I. Chalmers, and G. Bachrach. 2007. Coaggregation and distance-critical communication, p. 89-100. In K. A. Brogden, F. C. Minion, N. Cornick, T. B. Stanton, Q. Zhang, L. K. Nolan, and M. J. Wannemuehler (ed.), Virulence mechanisms of bacterial pathogens, 4th ed. ASM Press, Washington, DC.
23. Krugliak, M., R. Feder, V. Y. Zolotarev, L. Gaidukov, A. Dagan, H. Ginsburg, and A. Mor. 2000. Antimalarial activities of dermaseptin S4 derivatives. Antimicrob. Agents Chemother. 44:2442-2451.
24. Martin, M., J. Katz, S. N. Vogel, and S. M. Michalek. 2001. Differential induction of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli. J. Immunol. 167:5278-5285.
25. Marynka, K., S. Rotem, I. Portnaya, U. Cogan, and A. Mor. 2007. In vitro discriminative antipseudomonal properties resulting from acyl substitution of N-terminal sequence of dermaseptin S4 derivatives. Chem. Biol. 14:75-85.
26. Norskov-Lauritsen, N., and M. Kilian. 2006. Reclassification of Actinobacilius actinomycetemcomitans, Haemophilus aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter segnis comb, nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent and V factor-independent isolates. Int. J. Syst. Evol. Microbiol. 56:2135-2146.
27. Ouhara, K., H. Komatsuzawa, S. Yamada, H. Shiba, T. Fujiwara, M. Ohara, K. Sayama, K. Hashimoto, H. Kurihara, and M. Sugai. 2005. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 55:888-896.
28. Papo, N., and Y. Shai. 2005. A molecular mechanism for lipopolysaccharide protection of gram-negative bacteria from antimicrobial peptides. J. Biol. Chem. 280:10378-10387.
29. Peschel, A., R. W. Jack, M. Otto, L. V. Collins, P. Staubitz, G. Nicholson, H. Kalbacher, W. F. Nieuwenhuizen, G. Jung, A. Tarkowski, K. P. van Kessel, and J. A. van Strijp. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med. 193:1067-1076.
30. Peschel, A., M. Otto, R. W. Jack, H. Kalbacher, G. Jung, and F. Gotz. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410.
31. Pier, G. B. 2000. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc. Natl. Acad. Sci. USA 97:8822-8828.
32. Piers, K. L., M. H. Brown, and R. E. Hancock. 1994. Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification. Antimicrob. Agents Chemother. 38:2311-2316.
33. Pulendran, B., P. Kumar, C. W. Cutler, M. Mohamadzadeh, T. Van Dyke, and J. Banchereau. 2001. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 167:5067-5076.
34. Pütsep, K., G. Carlsson, H. G. Boman, and M. Andersson. 2002. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360:1144-1149.
35. Ruissen, A. L., J. Groenink, P. Krijtenberg, E. Walgreen-Weterings, W. van 't Hof, E. C. Veerman, and A. V. Nieuw Amerongen. 2003. Internalisation and degradation of histatin 5 by Candida albicans. Biol. Chem. 384:183-190.
36. Satcher, D. S. 2000. Oral health in America: a report of the Surgeon General.
37. Schmidtchen, A., I. M. Frick, E. Andersson, H. Tapper, and L. Bjorck. 2002. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. 46:157-168.
38. Scott, M. G., E. Dullaghan, N. Mookherjee, N. Glavas, M. Waldbrook, A. Thompson, A. Wang, K. Lee, S. Doria, P. Hamill, J. J. Yu, Y. Li, O. Donini, M. M. Guarna, B. B. Finlay, J. R. North, and R. E. Hancock. 2007. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25:465-472.
39. Shi, Y., D. B. Ratnayake, K. Okamoto, N. Abe, K. Yamamoto, and K. Nakayama. 1999. Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis. Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA. J. Biol. Chem. 274:17955-17960.
40. Socransky, S. S., A. D. Haffajee, M. A. Cugini, C. Smith, and R. L. Kent, Jr. 1998. Microbial complexes in subgingival plaque. J. Clin. Periodontol. 25:134-144.
41. Sørensen, O. E., P. Follin, A. H. Johnsen, J. Calafat, G. S. Tjabringa, P. S. Hiemstra, and N. Borregaard. 2001. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97:3951-3959.
42. Starner, T. D., W. E. Swords, M. A. Apicella, and P. B. McCray, Jr. 2002. Susceptibility of nontypeable Haemophilus influenzae to human β-defensins is influenced by lipooligosaccharide acylation. Infect. Immun. 70:5287-5289.
43. Yang, D., A. Biragyn, D. M. Hoover, J. Lubkowski, and J. J. Oppenheim. 2004. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 22:181-215.
44. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.
45. Zasloff, M. 2002. Innate immunity, antimicrobial peptides, and protection of the oral cavity. Lancet 360:1116-1117.